2. Search Result
Search Result
Results for "

Cholesterol efflux

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

6

Peptides

8

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0388
    Probucol
    2 Publications Verification

    DH-581

    		 Virus Protease Apoptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Caspase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases .
    Probucol
  • HY-129098
    DMHCA
    1 Publications Verification

    		 LXR Metabolic Disease
    DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes .
    DMHCA
  • HY-N0246
    Saikosaponin A
    5 Publications Verification

    		 LXR Bacterial Inflammation/Immunology Cancer
    Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
    Saikosaponin A
  • HY-P6306
    CS-6253
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
    CS-6253
  • HY-W020012
    Fluoresterol

    22-NBD Cholesterol

    		 Fluorescent Dye Metabolic Disease
    Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) .
    Fluoresterol
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-N2419
    Erythrodiol
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Erythrodiol is an olive oil component. Erythrodiol promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein. Erythrodiol is a good candidate to be further explored for therapeutic or preventive application in the context of atherosclerosis .
    Erythrodiol
  • HY-N0686
    Pseudoprotodioscin
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) MicroRNA Metabolic Disease
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .
    Pseudoprotodioscin
  • HY-W040150
    (24S,25)-Epoxycholesterol

    		LXR Neurological Disease Inflammation/Immunology Cancer
    24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux , inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells .
    (24S,25)-Epoxycholesterol
  • HY-P10551
    ApoA-I mimetic peptide 5A

    		Transmembrane Glycoprotein NF-κB TNF Receptor Cardiovascular Disease
    ApoA-I mimetic peptide 5A is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). ApoA-I mimetic peptide 5A can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. ApoA-I mimetic peptide 5A also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. ApoA-I mimetic peptide 5A can be used in the study of cardiovascular diseases .
    ApoA-I mimetic peptide 5A
  • HY-123402
    GSK3987
    2 Publications Verification

    		 LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation .
    GSK3987
  • HY-113365S
    Cholestenone-d5

    4-Cholesten-3-one-d5

    		 Endogenous Metabolite Metabolic Disease
    Cholestenone-d5 is the deuterium labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells .
    Cholestenone-d5
  • HY-W674245
    10-Hydroxyhexadecanoic acid

    		ATP-binding cassette (ABC) transporters Cardiovascular Disease
    10-Hydroxyhexadecanoic acid is a hydroxy fatty acid found in Camembert cheese. 10-Hydroxyhexadecanoic acid can promote cholesterol efflux from ABCA1 and ABCG1, preventing the accumulation of excess cholesterol in cells. 10-Hydroxyhexadecanoic acid can be used in anti-atherosclerosis research .
    10-Hydroxyhexadecanoic acid
  • HY-P6306A
    CS-6253 TFA
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
    CS-6253 TFA
  • HY-P2624A
    st-Ht31 ammonium

    		PAK Metabolic Disease
    st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .
    st-Ht31 ammonium
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid

    Sciadonic acid

    		 Apolipoprotein Inflammation/Immunology
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
  • HY-D2262
    BODIPY-cholesterol conjugate-2

    		Fluorescent Dye Metabolic Disease
    BODIPY-cholesterol conjugate-2 (compound 6) is a BODIPY-cholesterol conjugate. BODIPY-cholesterol conjugate-2 is a useful probe for simultaneous visualization of intracellular cholesterol pools and for monitoring cholesterol efflux from cells to extracellular acceptors. (λex=589 nm, λem=638 nm) .
    BODIPY-cholesterol conjugate-2
  • HY-W590664
    C2 Dihydroceramide

    		Endogenous Metabolite Cardiovascular Disease
    C2 Dihydroceramide is a derivative of C2 Ceramide (HY-101180). C2 Dihydroceramide enhances the ABCA1-mediated cholesterol efflux to apolipoprotein A-I (apoA-I) without causing cytotoxicity .
    C2 Dihydroceramide
  • HY-113365S2
    Cholestenone-13C2

    4-Cholesten-3-one-13C2

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Cholestenone- 13C2 is the 13C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells .
    Cholestenone-13C2
  • HY-P2624
    st-Ht31

    		PAK Metabolic Disease
    st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .
    st-Ht31
  • HY-124187
    Pinolenic acid ethyl ester

    Ethyl pinolenate

    		 Biochemical Assay Reagents Others
    Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
    Pinolenic acid ethyl ester
  • HY-113365S1
    Cholestenone-13C

    4-Cholesten-3-one-13C

    		 Endogenous Metabolite Metabolic Disease
    Cholestenone- 13C is the 13C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells .
    Cholestenone-13C
  • HY-N0246R
    Saikosaponin A (Standard)

    		Reference Standards LXR Bacterial Metabolic Disease Inflammation/Immunology
    Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
    Saikosaponin A (Standard)
  • HY-124273
    C2 L-threo Ceramide (d18:1/2:0)

    L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0); N-acetyl-L-threo-Sphingosine

    		 Endogenous Metabolite Cardiovascular Disease
    C2 L-threo Ceramide (d18:1/2:0) (L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0)) is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide. C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.
    C2 L-threo Ceramide (d18:1/2:0)
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-117555
    4010B-30

    		Apolipoprotein PPAR ATP-binding cassette (ABC) transporters Cardiovascular Disease
    4010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE -/- mice .
    4010B-30
  • HY-D2261
    BODIPY-cholesterol conjugate-1

    		Fluorescent Dye Metabolic Disease
    BODIPY-cholesterol conjugate-1 (compound 5) is a BODIPY-cholesterol conjugate. BODIPY-cholesterol conjugate-1 is a useful probe for simultaneous visualization of intracellular cholesterol pools and for monitoring cholesterol efflux from cells to extracellular acceptors . (λex 541 nm, λem 615 nm).
    BODIPY-cholesterol conjugate-1
  • HY-P5878
    RG33 Peptide

    		Biochemical Assay Reagents Metabolic Disease
    RG33 Peptide is a diabetes inhibitor that significantly improves glucose clearance in insulin-resistant mice. RG33 Peptide effectively solubilizes lipid vesicles and promotes cholesterol efflux in cultured macrophages. RG33 Peptide is used in research into type 2 diabetes (T2D) .
    RG33 Peptide
  • HY-N2419R
    Erythrodiol (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Erythrodiol (Standard) is the analytical standard of Erythrodiol. This product is intended for research and analytical applications. Erythrodiol is an olive oil component. Erythrodiol promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein. Erythrodiol is a good candidate to be further explored for therapeutic or preventive application in the context of atherosclerosis .
    Erythrodiol (Standard)
  • HY-N0686R
    Pseudoprotodioscin (Standard)

    		Reference Standards Fatty Acid Synthase (FASN) MicroRNA Metabolic Disease
    Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .
    Pseudoprotodioscin (Standard)
  • HY-115780
    E17110

    		LXR ATP-binding cassette (ABC) transporters Cardiovascular Disease
    E17110 is a liver X receptor β (LXRβ) agonist with an EC50 of 0.72 μM. E17110 can increase the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 macrophages. E17110 also reduce cellular lipid accumulation and promoted cholesterol efflux. E17110 can be used for the research of cardiovascular disease, such as atherosclerosis .
    E17110
  • HY-129289
    NSC 13987

    		HIV Infection Inflammation/Immunology
    NSC 13987 is a Nef site I inhibitor. NSC 13987 binds to Nef site I and disrupts the Nef-calnexin interaction. NSC 13987 restores cholesterol efflux inhibited by Nef. NSC 13987 is applicable to the research of HIV-associated atherosclerosis .
    NSC 13987
  • HY-W1120833
    m-PEG26-NHS ester

    		Biochemical Assay Reagents Neurological Disease Metabolic Disease
    m-PEG26-NHS ester is a PEG derivative. m-PEG26-NHS ester can be used for the study of Niemann-Pick type C1 disease .
    m-PEG26-NHS ester
  • HY-181520
    ABCA1 inducer 3

    		ATP-binding cassette (ABC) transporters Metabolic Disease
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia .
    ABCA1 inducer 3
  • HY-182938
    Autophagy activator-2

    		Autophagy Metabolic Disease
    Autophagy activator-2 is a potent autophagy activator with EC50 values of 14.33 μM. Autophagy activator-2 acts as a proteostasis modulator and small-molecule chaperone that upregulates I1061T mutant NPC1 expression and facilitates cholesterol efflux. Autophagy activator-2 reduces lysosomal hydrolase levels. Autophagy activator-2 can be used for the study of Niemann-Pick Type C disease .
    Autophagy activator-2
  • HY-120433
    BLT-3

    		Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease .
    BLT-3
  • HY-186045
    SKLB06489

    		Histone Methyltransferase Apoptosis DNA/RNA Synthesis ATP-binding cassette (ABC) transporters Cancer
    SKLB06489 is a selective and orally active inhibitor of type I PRMT enzymes, with IC50 values of 64.55 nM (PRMT1), 4.21 nM (PRMT6), and 51.27 nM (PRMT8). SKLB06489 inhibits cell proliferation, colony formation, DNA replication, and DNA damage repair in cancer cells. SKLB06489 induces G0/G1-phase cell cycle arrest and apoptosis in cancer cells. SKLB06489 enhances intracellular cholesterol efflux via ABCA1 and ABCG1 upregulation, disrupts cholesterol metabolic homeostasis, and suppresses tumor growth in subcutaneous xenograft models. SKLB06489 can be used for the research of triple-negative breast cancer (TNBC) .
    SKLB06489
  • HY-181509
    TNF-α/IL-1β/IL-6-IN-1

    		Reactive Oxygen Species (ROS) Interleukin Related ATP-binding cassette (ABC) transporters Inflammation/Immunology
    TNF-α/IL-1β/IL-6-IN-1 is an anti-inflammatory agent. TNF-α/IL-1β/IL-6-IN-1 exerts anti-inflammatory effects by downregulating the expression of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6, and inhibiting the production of ROS. TNF-α/IL-1β/IL-6-IN-1 upregulates ABCG1 to promote cholesterol efflux. TNF-α/IL-1β/IL-6-IN-1 can be used in the research of inflammatory and lipid metabolic diseases such as atherosclerosis .
    TNF-α/IL-1β/IL-6-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: